Grundlæggende statistik
| LEI | 549300WQE5EI9R35SE66 |
| CIK | 1641489 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to vTv Therapeutics Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| September 2, 2025 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK OF VTV THERAPEUTICS INC. EX-4.1 EXHIBIT 4.1 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN TH |
|
| September 2, 2025 |
EX-10.2 EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of August 29, 2025 by and among vTv Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several investors signatory hereto (each, a “Investor” and collectively, the “Investors”). RECITALS WHEREAS, the Company and the |
|
| September 2, 2025 |
EX-10.1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of August 29, 2025, by and among vTv Therapeutics Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Company and the Investors are executing an |
|
| September 2, 2025 |
FORM OF WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS OF VTV THERAPEUTICS INC. EX-4.2 EXHIBIT 4.2 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN TH |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 vTv Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37524 47-3916571 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 12, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2025 |
Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update •First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •Cadisegliatin intellectual property portfolio expanded •Leadership team strengthened HIGH POINT, N.C., August 12, 2025 (GLOBE NEWS |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 10, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 19, 2025 |
Exhibit 99.1 vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) - vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Finan |
|
| May 19, 2025 |
1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of May 12, 2025, by and between vTv Therapeutics LLC, a Delaware limited liability company (the “Company”), and Michael Tung (the “Executive”), and for certain purposes specified herein, only, vTv Therapeutics Inc. |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 19, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission File |
|
| May 16, 2025 |
1 Nasdaq: VTVT Improving the Lives of Millions of People Living with Type 1 Diabetes May 2025 2 THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. |
|
| May 16, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 16, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2025 |
Exhibit 99.1 vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical compan |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 15, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 11, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 31, 2025 |
1 Nasdaq: VTVT Improving the Lives of Millions of People Living with Type 1 Diabetes March 2025 2 THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 31, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 20, 2025 |
Trading Policy of vTv Therapeutics Inc. VTV THERAPEUTICS INC. AMENDED AND RESTATED SECURITIES TRADING POLICY March 18, 2024 To Directors, Officers and Employees of vTv Therapeutics Inc. and its subsidiaries (collectively, the “Company”): Attached is the Amended and Restated Securities Trading Policy (the “Policy”) for directors, officers and employees of the Company, which has been adopted by the Board of Directors on March 12, 2024, an |
|
| March 20, 2025 |
Exhibit 4.6 DESCRIPTION OF THE CAPITAL STOCK Capital Stock Our authorized capital stock consists of 200,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of March 20, 2025, we have approximately 2,612,257 shares of our Class A common stock |
|
| March 20, 2025 | ||
| March 20, 2025 |
Exhibit 99.1 vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., Mar |
|
| March 20, 2025 |
, by and between Newsoara Biopharma Co., Ltd., and vTv Therapeutics LLC FIRST AMENDMENT TO LICENSE AGREEMENT THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is entered into this 11th day of November 2020 (the “Amendment Effective Date”), by and between NEWSOARA BIOPHARMA CO. |
|
| March 20, 2025 | ||
| March 20, 2025 | ||
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 20, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| March 20, 2025 |
Subsidiaries of vTv Therapeutics Inc. Exhibit 21.1 vTv Therapeutics Inc. Corporate Subsidiaries as of March 20, 2025 Subsidiary Jurisdiction of Incorporation vTv Therapeutics LLC Delaware |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 14, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2025 |
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 24, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 13, 2025 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| January 13, 2025 |
1 Nasdaq: VTVT Improving the Lives of Millions of People Living with Type 1 Diabetes January 2025 2 THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 12, 2024 |
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C., November 12, 2024 (GLOBENEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 12, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): October 22, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| September 23, 2024 |
As filed with the United States Securities and Exchange Commission on September 23, 2024 As filed with the United States Securities and Exchange Commission on September 23, 2024 Registration No. |
|
| September 23, 2024 |
vTv Therapeutics Inc. 2024 Equity Incentive Plan Exhibit 4.5 APPENDIX A vTv THERAPEUTICS INC. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 23, 2024 APPROVED BY THE STOCKHOLDERS: June 11, 2024 AGM DATE: June 11, 2024 1.GENERAL. (a)Design of a New Plan. The Plan is intended to replace the vTv Therapeutics Inc. 2015 Equity Incentive Plan, as amended (the “Prior Plan”). From and after 12:01 a.m. Eastern time on the AGM Date |
|
| September 23, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) vTv Therapeutics Inc. |
|
| August 8, 2024 |
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., August 8, 2024 |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 8, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 26, 2024 |
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold HIGH POINT, N. |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 26, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 26, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 11, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 9, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission File |
|
| May 9, 2024 |
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. – May 9, 2024 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 29, 2024 |
vTv Therapeutics Inc. Class A Common Stock Preferred Stock Debt Securities Table of Contents Filed pursuant to Rule 424(b)(2) Registration No. 333-278612 vTv Therapeutics Inc. $250,000,000 Class A Common Stock Preferred Stock Debt Securities Warrants Rights Units This prospectus contains a general description of the securities that we may offer for sale with an aggregate offering price of up to $250,000,000 from time to time in one or more offerings. Each time we offer a |
|
| April 29, 2024 |
Up to $12,678,712 vTv Therapeutics Inc. Class A Common Stock Filed Pursuant to Rule 424(b)(2) Registration No. 333-278612 PROSPECTUS Up to $12,678,712 vTv Therapeutics Inc. Class A Common Stock We have entered into a sales agreement, or sales agreement, with Cowen and Company, LLC, or TD Cowen, relating to shares of our Class A common stock, $0.01 par value per share, offered by this prospectus. In accordance with the terms of the sales agreement, from time |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| April 25, 2024 |
April 25, 2024 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) vTv Therapeutics, Inc. |
|
| April 10, 2024 |
Form of indenture to be entered into between registrant and a trustee acceptable to the registrant. Exhibit 4.2 VTV THERAPEUTICS INC., AS ISSUER, AND [TRUSTEE], AS TRUSTEE, INDENTURE DATED AS OF , 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificat |
|
| April 10, 2024 |
As filed with the Securities and Exchange Commission on April 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 10, 2024 Registration No. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 25, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 22, 2024 |
VTVT / vTv Therapeutics Inc. / MacAndrews & Forbes Inc. - AMENDMENT NO. 45 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 45)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385204 (CUSIP Number) Jeffrey A. Brodsky Chief Financial Officer MacAndrews & Forbes Incorporated 31 East 62nd Street New York, NY |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 13, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 13, 2024 |
Exhibit 4.6 DESCRIPTION OF THE CAPITAL STOCK Capital Stock Our authorized capital stock consists of 200,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of March 13, 2024, we have approximately 2,432,857 shares of our Class A common stock |
|
| March 13, 2024 |
Exhibit 99.1 vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update •Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund. •Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin, for the treatment of type 1 diabetes, expected to initiate patie |
|
| March 13, 2024 |
Certificate of Amendment of Certificate of Incorporation dated as of November 20, 2023. Delaware The First State Page 1 5718082 8100 Authentication: 204634511 SR# 20234021760 Date: 11-20-23 You may verify this certificate online at corp. |
|
| March 13, 2024 |
VTV THERAPEUTICS INC. CLAWBACK POLICY vTv Therapeutics Inc. (the “Company”) has adopted this clawback policy (“Policy”) in accordance with Nasdaq listing requirements. A.Application of Policy This Policy applies in the event of any accounting restatement (“Restatement”) due to the Company’s material non-compliance with financial reporting requirements under applicable securities laws, in accordanc |
|
| March 13, 2024 |
, Inc. Common Stock Repurchase Agreement dated as of Octo RENEO PHARMACEUTICALS, INC. COMMON STOCK REPURCHASE AGREEMENT THIS COMMON STOCK REPURCHASE AGREEMENT Agreement October 30, 2023 Effective Date between vTv Therapeutics LLC Stockholder and Reneo Pharmaceuticals, Inc. Company Party Parties RECITALS The Stockholder desires and voluntarily agrees to sell to the Company an aggregate of 576,443 Repurchased Shares Repurchase he Repurchase, the Parties ha |
|
| March 13, 2024 |
Subsidiaries of vTv Therapeutics Inc. Exhibit 21.1 vTv Therapeutics Inc. Corporate Subsidiaries as of March 13, 2024 Subsidiary Jurisdiction of Incorporation vTv Therapeutics LLC Delaware |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 13, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| March 13, 2024 | ||
| March 13, 2024 | ||
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 5, 2024 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 5, 2024 |
EX-99.1 2 tm248032d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of vTv Therapeutics Inc. This |
|
| March 5, 2024 |
VTVT / vTv Therapeutics Inc. / BAKER BROS. ADVISORS LP - SC 13D Activist Investment SC 13D 1 tm248032d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* vTv Therapeutics Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 918385204 (CUSIP number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washin |
|
| March 5, 2024 |
Improving the Lives of Millions of Patients with Type 1 Diabetes Nasdaq: VTVT THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. |
|
| March 5, 2024 |
EX-99.3 3 tm248032d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 March 5, 2024 vTv Therapeutics Inc. 3980 Premier Drive Suite 310 High Point, North Carolina 27265 Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of vTv Therapeutics Inc., a Delaware corporation (the “Company”), and the holders of the shares of Class A common stock, par valu |
|
| March 5, 2024 |
VTVT / vTv Therapeutics Inc. / Samsara BioCapital, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, $0.01 par value per share (Title of Class of Securities) 918385204 (CUSIP Number) Abrar Hussain Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA 94301 (650) 285-4270 (Name, Address |
|
| February 28, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 27, 2024, by and among vTv Therapeutics Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Company and the Investors are executing |
|
| February 28, 2024 |
EX-99.1 Exhibit 99.1 vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024 HIGH POINT, N.C., February 28, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the develop |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 vTv Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter)\ Delaware 001-37524 47-3916571 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 28, 2024 |
Up to $4,923,802 vTv Therapeutics Inc. Class A Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254445 PROSPECTUS SUPPLEMENT (To Prospectus dated April 20, 2021) Up to $4,923,802 vTv Therapeutics Inc. Class A Common Stock We have entered into a sales agreement, or sales agreement, with Cowen and Company, LLC, or TD Cowen, relating to shares of our Class A common stock, $0.01 par value per share, offered by this pro |
|
| February 28, 2024 |
EX-10.3 Exhibit 10.3 FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT THIS FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT (this “Amendment”) is entered into this 27th day of February, 2024 (the “Effective Date”), by and between G42 Investments AI Holdings RSC Ltd (“G42”), a private limited company incorporated in the Abu Dhabi Global Market and vTv Therapeutics Inc., a Delaware corporation ( |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 vTv Therapeutics Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2024 |
EX-10.5 Exhibit 10.5 FIRST AMENDMENT TO INVESTOR RIGHTS AGREEMENT THIS FIRST AMENDMENT TO INVESTOR RIGHTS AGREEMENT (this “Amendment”) is entered into this 27th day of February, 2024 (the “Effective Date”), by and between M&F TTP Holdings Two LLC (as successor in interest to vTv Therapeutics Holdings LLC) (“Holdings”), a Delaware limited liability company, and vTv Therapeutics Inc., a Delaware cor |
|
| February 28, 2024 |
EX-10.4 Exhibit 10.4 FIRST AMENDMENT TO COMMON STOCK AND WARRANT PURCHASE AGREEMENT THIS FIRST AMENDMENT TO COMMON STOCK AND WARRANT PURCHASE AGREEMENT (this “Amendment”) is entered into this 27th day of February, 2024 (the “Effective Date”), by and between CinPax, LLC (“CinPax”), an Ohio limited liability company, CinRx Pharma, LLC (“CinRx”), an Ohio limited liability company, and vTv Therapeutic |
|
| February 28, 2024 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of February 27, 2024 by and between vTv Therapeutics Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this |
|
| February 28, 2024 |
EX-4.1 Exhibit 4.1 THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN TH |
|
| February 28, 2024 |
Exhibit 1.1 VTV THERAPEUTICS INC. $50,000,000 CLASS A COMMON STOCK SALES AGREEMENT February 28, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: vTv Therapeutics Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time duri |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 18, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 13, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 11, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 20, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 15, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| November 15, 2023 |
vtvtherapeuticsdeck-nonx Improving the Lives of Millions of Patients with Type 1 Diabetes NASDAQ: VTVT THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 14, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 09, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2023 |
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - November 9, 2023 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for th |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 1, 2023 |
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million Exhibit 99.1 vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million HIGH POINT, N.C., November 1, 2023 (GLOBE NEWSWIRE) - vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): October 30, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement vTv Therapeutics Inc. (Name of Registrant as Spe |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement vTv Therapeutics Inc. (Name of Registrant as Spe |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 11, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission F |
|
| August 11, 2023 |
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - August 11, 2023 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for th |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 17, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 21, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 6, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 11, 2023 |
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. - May 11, 2023 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 11, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission File |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement. |
|
| March 6, 2023 |
Exhibit 99.1 vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update •Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes •Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial Officer •Biotech industry vetera |
|
| March 6, 2023 |
Subsidiaries of vTv Therapeutics Inc. Exhibit 21.1 vTv Therapeutics Inc. Corporate Subsidiaries as of March 6, 2023 Subsidiary Jurisdiction of Incorporation vTv Therapeutics LLC Delaware |
|
| March 6, 2023 |
Exhibit 10.36 THIS DEED OF NOVATION is made on 21 December 2022 PARTIES: (1)VTV THERAPEUTICS LLC, a Delaware limited liability company having an address at 3980 Premier Dr. Suite 310, High Point, North Carolina 27265, United States of America (the "Continuing Party"); (2)G42 HEALTHCARE RESEARCH TECHNOLOGY PROJECTS LLC, a company registered in Abu Dhabi whose registered address is at Capital Gate T |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 6, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 6, 2023 |
EX-10.37 3 vtvt-20221231xexx1037varia.htm EX-10.37 CONFIDENTIAL Exhibit 10.37 THIS DEED OF VARIATION (“DEED”) is made on February 28 , 2023 (the “Effective Date”) PARTIES: (1)vTv THERAPEUTICS INC., a Delaware corporation (“vTv”); (2)G42 INVESTMENTS AI HOLDING RSC LTD., a private limited company incorporated in the Abu Dhabi Global Market with registered number 000003845 and with its registered add |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| February 1, 2023 |
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics EXHIBIT 99.1 Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics HIGH POINT, N.C., February 1, 2023 (GLOBE NEWSWIRE) - vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executi |
|
| February 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 1, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| January 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 6, 2023 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47 |
|
| January 6, 2023 |
EX-99.1 2 eh230318442ex9901.htm EXHIBIT 99.1 EXHIBIT 99.1 NASDAQ: VTVT Improving the Lives of Millions of Patients with Type 1 Diabetes Non - Confidential vTv Therapeutics THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD - LOOKING STATEMENTS REGARDING (I) DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVES |
|
| December 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 22, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| December 13, 2022 |
EX-10.1 2 eh220309936ex1001.htm EXHIBIT 10.1 EXHIBIT 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of December 8, 2022, by and between vTv Therapeutics LLC, a Delaware limited liability company (the “Company”), and Steven Tuch (the “Executive”), and for certain purposes specified herein only, vTv Therapeutics Inc., a Delaware corporation (“vTv”). WHEREAS the Compa |
|
| December 13, 2022 |
EXHIBIT 99.1 Steven Tuch, Chief Financial Officer vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer HIGH POINT, N.C. – December 13, 2022 — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Ch |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 8, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| November 10, 2022 |
Exhibit 99.1 vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update •Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 •Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of Directors. •Agreements with CinRx Pharma and a subsidiary to provide additional capita |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 10, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| August 23, 2022 |
VTVT / vTv Therapeutics Inc / Medpace Investors, Llc - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 vTv Therapeutics Inc. |
|
| August 15, 2022 |
EXECUTION VERSION COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (the ?Agreement?) is entered into as of May 31, 2022 (the ?Effective Date?), by and between vTv Therapeutics LLC, a Delaware limited liability company having an address at 3980 Premier Dr. |
|
| August 15, 2022 |
Exhibit 99.1 vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update ?Paul Sekhri appointed as President, Chief Executive Officer and Board member. ?Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx?s industry experience to collaborate in overseeing TTP399 clinical trials. ?Entered into agreement |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 15, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission F |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 9, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47- |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 27, 2022 |
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer EXHIBIT 99.1 vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer HIGH POINT, N.C. ? (GLOBE NEWSWIRE) ? July 27, 2022 ? vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that Paul Sekhri will lead the company as President and Chief Ex |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 25, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-3 |
|
| July 27, 2022 |
EXHIBIT 10.2 VTV THERAPEUTICS INC. INDUCEMENT AWARD NONQUALIFIED OPTION AWARD AGREEMENT THIS INDUCEMENT AWARD NONQUALIFIED OPTION AWARD AGREEMENT (the ?Agreement?), is entered into as of July 26, 2022 (the ?Date of Grant?), by and between vTv Therapeutics Inc., a Delaware corporation (the ?Company?), and Paul Sekhri (the ?Participant?). WHEREAS, the Board has determined that it is in the best inte |
|
| July 27, 2022 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of July 25, 2022, by and between vTv Therapeutics LLC, a Delaware limited liability company (the ?Company?), and Paul Sekhri (the ?Executive?), and for certain purposes specified herein, only, vTv Therapeutics Inc., a Delaware corporation (?vTv?). WHEREAS, the Company desires to employ the Executive, and the Executive is willing |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 22, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-37524 47-3916571 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 25, 2022 |
Exhibit 10.1 EXECUTION VERSION COMMON STOCK AND WARRANT PURCHASE AGREEMENT This Common Stock and Warrant Purchase Agreement (this ?Agreement?) is dated as of July 22, 2022, by and among vTv Therapeutics Inc., a Delaware corporation (the ?Company?), CinPax, LLC, an Ohio limited liability company (the ?Purchaser?), and CinRx Pharma, LLC, an Ohio limited liability company (?HoldCo?). WHEREAS, on the |
|
| July 25, 2022 |
vTv Therapeutics Announces Investment by CinRx Pharma Exhibit 99.1 vTv Therapeutics Announces Investment by CinRx Pharma HIGH POINT, N.C.?(GLOBE NEWSWIRE)?July 25, 2022 ? vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (?CinPax?), a subsidiary of CinRx Pharma, LLC (?CinRx?). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv |
|
| July 25, 2022 |
Exhibit 4.1 EXECUTION VERSION WARRANT THE SECURITIES EVIDENCED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTI |
|
| July 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 11, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-3 |
|
| June 10, 2022 |
Exhibit 99.3 POWER OF ATTORNEY Know all by these present that the undersigned hereby constitutes and appoints Mr Martin Edelman of Paul Hastings LLP, as the undersigned’s true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or ultimate beneficial holder of 10% or more of a registered class of securities of |
|
| June 10, 2022 |
Joint Filing Agreement, dated June 10, 2022 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules the |
|
| June 10, 2022 |
COMMON STOCK PURCHASE AGREEMENT Exhibit 99.2 EXECUTION VERSION COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 31, 2022 by and among vTv Therapeutics Inc., a Delaware corporation (the “Company”), G42 Investments AI Holding RSC Ltd, a private limited company incorporated in the Abu Dhabi Global Market with registered number 000003845 and with its registered address at Off |
|
| June 10, 2022 |
VTVT / vTv Therapeutics Inc / G42 Investments AI Holdings RSC Ltd. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) * vTv Therapeutics Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 918385105 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 31, 2022 (Date of Event W |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 1, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-39 |
|
| June 1, 2022 |
VTVT / vTv Therapeutics Inc / MacAndrews & Forbes Inc. - SC 13DA Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 44)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385 105 (CUSIP Number) Jeffrey A. Brodsky Chief Financial Officer MacAndrews & Forbes Incorporated 31 East 62nd Street New York, N |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 31, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-39 |
|
| June 1, 2022 |
EXHIBIT 99.1 vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare HIGH POINT, N.C.-(GLOBE NEWSWIRE)- June 1, 2022 - vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (?G42 Investments?). Under the terms of the agreements, G42 |
|
| June 1, 2022 |
EX-1.1 2 eh220257384ex0101.htm EXHIBIT 1.1 EXHIBIT 1.1 EXECUTION VERSION COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 31, 2022 by and among vTv Therapeutics Inc., a Delaware corporation (the “Company”), G42 Investments AI Holding RSC Ltd, a private limited company incorporated in the Abu Dhabi Global Market with registered number 000003 |
|
| May 12, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of March 1, 2022, by and between vTv Therapeutics LLC, a Delaware limited liability company (the ?Company?), and Richard S. Nelson (the ?Executive?), and for certain purposes specified herein, only, vTv Therapeutics Inc., a Delaware corporation (?vTv?). WHEREAS, the Company desires to employ the Executive on an interim basis, an |
|
| May 12, 2022 |
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. ? (GLOBE NEWSWIRE) ? May 12, 2022 ? vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs. Recent Achievements and Outlook Corporate ? Strategic Focus. W |
|
| May 12, 2022 |
and between vTv Therapeutics LLC and Deepa Prasad (incorporated by reference from Exhibit 10.1 Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE vTv Therapeutics LLC (the "Company") and Deepa Prasad, her heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as "Executive"), enter into this Separation Agreement and Mutual Release (the "Agreement), and agree that: WHEREAS, Executive has notified the Company of her intention to resign |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 12, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-39 |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Thera |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 15, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47- |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 30, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47- |
|
| March 29, 2022 |
Subsidiaries of vTv Therapeutics Inc. Exhibit 21.1 vTv Therapeutics Inc. Corporate Subsidiaries as of March 29, 2022 Subsidiary Jurisdiction of Incorporation vTv Therapeutics LLC Delaware |
|
| March 29, 2022 |
Exhibit 4.3 DESCRIPTION OF THE CAPITAL STOCK Capital Stock Our authorized capital stock consists of 200,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of March 29, 2022, we have approximately 66,942,777 shares of our Class A common stock |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeuti |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 29, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47- |
|
| March 29, 2022 |
Exhibit 99.1 vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update HIGH POINT, N.C. ? (GLOBE NEWSWIRE) ? March 29, 2022 ? vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on the progress of its clinical programs. ?I am dedicated to the long-ter |
|
| March 3, 2022 |
EXHIBIT 3.1 SECOND AMENDED AND RESTATED BY-LAWS of vtv therapeutics INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 STOCKHOLDERS 3 ARTICLE 3 DIRECTORS 11 ARTICLE 4 COMMITTEES OF THE BOARD 19 ARTICLE 5 OFFICERS 19 ARTICLE 6 GENERAL PROVISIONS 22 ARTICLE 1 DEFINITIONS As used in these By-laws, unless the context otherwise requires, the term: 1.1 ?Assistant Secr |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 27, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| February 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 17, 2022 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| December 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 6, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 1, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| December 2, 2021 |
EXHIBIT 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE vTv Therapeutics LLC (the ?Company?) and Rudy C. Howard, his heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as ?Employee?), agree that: WHEREAS, Employee desires to resign from the Company and his last day of employment is December 1, 2021; and WHEREAS, the parties are entering into |
|
| November 12, 2021 |
VTVT / vTv Therapeutics Inc / MacAndrews & Forbes Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 43)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385 105 (CUSIP Number) Shiri Ben-Yishai Executive Vice President and Chief Legal Officer MacAndrews & Forbes Incorporated 31 East |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 9, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| November 9, 2021 |
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. ? (GLOBE NEWSWIRE) ? November 9, 2021 ? vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs. ?We plan to refocus vTv?s strategy on TTP399. TTP399 i |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv T |
|
| October 20, 2021 |
vTv Therapeutics Announces Deepa Prasad as New President and CEO EXHIBIT 99.1 vTv Therapeutics Announces Deepa Prasad as New President and CEO HIGH POINT, N.C., Oct. 20, 2021 at 9am (GLOBE NEWSWIRE) - vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as President and Chief Executive |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): October 19, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| October 20, 2021 |
EXHIBIT 10.3 VTV THERAPEUTICS INC. INDUCEMENT AWARD NONQUALIFIED OPTION AWARD AGREEMENT THIS INDUCEMENT AWARD NONQUALIFIED OPTION AWARD AGREEMENT (the ?Agreement?), is entered into as of October 19, 2021 (the ?Date of Grant?), by and between vTv Therapeutics Inc., a Delaware corporation (the ?Company?), and Deepa Prasad (the ?Participant?). WHEREAS, the Board has determined that it is in the best |
|
| October 20, 2021 |
EXHIBIT 10.1 RETIREMENT AGREEMENT AND GENERAL RELEASE vTv Therapeutics LLC (the ?Company?) and Stephen L. Holcombe, his heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as ?Employee?), agree that: WHEREAS, Employee desires to retire from the Company and his last day of employment is October 19, 2021; and WHEREAS, the parties are entering |
|
| October 20, 2021 |
EXHIBIT 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of October 19, 2021, by and between vTv Therapeutics LLC, a Delaware limited liability company (the ?Company?), and Deepa Prasad (the ?Executive?), and for certain purposes specified herein, only, vTv Therapeutics Inc., a Delaware corporation (?vTv?). WHEREAS, the Company desires to employ the Executive, and the Executive is wil |
|
| September 17, 2021 |
VTVT / vTv Therapeutics Inc / MacAndrews & Forbes Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 42)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385 105 (CUSIP Number) Shiri Ben-Yishai Executive Vice President and Chief Legal Officer MacAndrews & Forbes Incorporated 31 East |
|
| August 4, 2021 |
Exhibit 10.1 AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT BY AND BETWEEN NOVO NORDISK A/S AND TRANSTECH PHARMA, INC. DATED AS OF FEBRUARY 20, 2007 * Certain information identified by ?[***]? has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ARTICLE I DEFINITIONS TABLE OF CONTENTS 1 1.1 ?Act? 2 1.2 ?Affil |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 vtvt-8k20210804.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 4, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-3 |
|
| August 4, 2021 |
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update Exhibit 99.1 vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. ? (GLOBE NEWSWIRE) ? August 4, 2021 ? vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs. ?We held our first, highly-productive meeting with the FDA |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therap |
|
| August 4, 2021 |
Amended and Restated Certificate of Incorporation, as amended. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF VTV THERAPEUTICS INC. vTv Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: The certificate of incorporation of the Corporation as heretofore in effect is hereby amended by amending and restating Section 4.1 thereof to provid |
|
| June 25, 2021 |
vTv Therapeutics Inc. Up to $50,000,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-254445 PROSPECTUS SUPPLEMENT (To Prospectus dated April 20, 2021) vTv Therapeutics Inc. Up to $50,000,000 Class A Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our Class A common stock, $0.01 par value per share, off |
|
| June 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 25, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-3 |
|
| June 15, 2021 |
9,437,376 Shares of Class A Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-256755 PROSPECTUS 9,437,376 Shares of Class A Common Stock This prospectus relates to the resale or other disposition from time to time of up to 9,437,376 shares of our Class A common stock by Lincoln Park Capital Fund, LLC (the ?selling stockholder? or ?Lincoln Park?). The shares of our Class A common stock that may be offered by Lincoln Park |
|
| June 9, 2021 |
vTv Therapeutics Inc. 3980 Premier Drive Suite 310 High Point, NC 27265 June 9, 2021 CORRESP 1 filename1.htm vTv Therapeutics Inc. 3980 Premier Drive Suite 310 High Point, NC 27265 June 9, 2021 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Fredrick Philantrope vTv Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-256755) Dear Mr. Philantrope: Pursuant to Rule 461 of the Securities |
|
| June 3, 2021 |
As filed with the Securities and Exchange Commission on June 3, 2021 As filed with the Securities and Exchange Commission on June 3, 2021 Registration No. |
|
| May 5, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF VTV THERAPEUTICS INC. vTv Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: The certificate of incorporation of the Corporation as heretofore in effect is hereby amended by amending and restating Section 4.1 thereof to provid |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 5, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-391 |
|
| May 5, 2021 |
Exhibit 99.1 vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of HPP737 HIGH POINT, N.C. ? (GLOBE NEWSWIRE) ? May 5, 2021 ? vTv Therapeutics Inc. (Nasdaq:VTVT) toda |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Thera |
|
| April 21, 2021 |
vTv Therapeutics Inc. Up to $5,500,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-254445 PROSPECTUS vTv Therapeutics Inc. Up to $5,500,000 Class A Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our Class A common stock, $0.01 par value per share, offered by this prospectus. In accordance with the t |
|
| April 16, 2021 |
vTv Therapeutics Inc. 3890 Premier Drive Suite 310 High Point, NC 27265 April 16, 2021 vTv Therapeutics Inc. 3890 Premier Drive Suite 310 High Point, NC 27265 April 16, 2021 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell vTv Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-254445) Dear Mr. Campbell: Pursuant to Rule 461 of the Securities Act of 1933, as amended, we here |
|
| April 9, 2021 |
As filed with the Securities and Exchange Commission on April 9, 2021 Registration No. |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| February 24, 2021 |
Exhibit 10.36 * Certain information identified by ?[***]? has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. FIRST AMENDMENT TO LICENSE AGREEMENT THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this ?Amendment?) is entered into this 14th day of January, 2021 (the ?Effective Date?), by and between HANGZHOU ZHONGMEI H |
|
| February 24, 2021 |
Exhibit 4.3 DESCRIPTION OF THE CAPITAL STOCK Capital Stock Our authorized capital stock consists of 100,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of February 24, 2021, we have approximately 57,550,710 shares of our Class A common st |
|
| February 24, 2021 |
Exhibit 10.35 * Certain information identified by ?[***]? has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE Agreement This License Agreement (the ?Agreement?) is entered into as of December 11, 2020 (the ?Effective Date?), by and between Anteris Bio, Inc., a Delaware corporation having an address at 11 |
|
| February 24, 2021 |
Subsidiaries of vTv Therapeutics Inc. Exhibit 21.1 vTv Therapeutics Inc. Corporate Subsidiaries as of February 24, 2021 Subsidiary Jurisdiction of Incorporation vTv Therapeutics LLC Delaware |
|
| February 24, 2021 |
Exhibit 99.1 vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA?s Diabetes Care Journal HIGH POINT, N.C. ? (GLOBE NEWSWIRE) |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 24, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therapeuti |
|
| January 21, 2021 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 14, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| January 14, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 14, 2021 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| January 14, 2021 |
vTv Therapeutics Inc. Up to $5,500,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-223269 PROSPECTUS SUPPLEMENT (To Prospectus dated March 19, 2018) vTv Therapeutics Inc. Up to $5,500,000 Class A Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our Class A common stock, $0.01 par value per share, offe |
|
| December 30, 2020 |
EX-10.1 2 vtvt-ex1016.htm EX-10.1 Exhibit 10.1 EXECUTION COPY EXECUTIVE CHAIRPERSON AGREEMENT THIS EXECUTIVE CHAIRPERSON AGREEMENT, dated as of December 30, 2020 (the “Execution Date”), is by and between vTv Therapeutics Inc., a Delaware corporation (the “Company”), and Robin E. Abrams (the “Executive Chairperson”). WHEREAS, the Executive Chairperson currently serves as the Executive Vice Presiden |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 23, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| December 17, 2020 |
Unregistered Sales of Equity Securities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 17, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| December 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 41)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385 105 (CUSIP Number) Frances Townsend Vice Chairman, General Counsel and Chief Administrative Officer MacAndrews & Forbes Incorp |
|
| December 15, 2020 |
Entry into a Material Definitive Agreement - VTVT-2020-12-15-8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 11, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| December 10, 2020 |
VTVT / vTv Therapeutics Inc / MacAndrews & Forbes Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 40)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385 105 (CUSIP Number) Frances Townsend Vice Chairman, General Counsel and Chief Administrative Officer MacAndrews & Forbes Incorp |
|
| December 10, 2020 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of December 10, 2020, by and between vTv Therapeutics LLC, a Delaware limited liability company (the ?Company?), and Rudy C. Howard (the ?Executive?), and for certain purposes specified herein, only, vTv Therapeutics Inc., a Delaware corporation (?vTv?). WHEREAS, the Company desires to continue to employ the Executive, and the E |
|
| December 10, 2020 |
8-K 1 vtvt-8k20201210.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): December 10, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 00 |
|
| December 10, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of December 10, 2020, by and between vTv Therapeutics LLC, a Delaware limited liability company (the ?Company?), and Stephen L. Holcombe (the ?Executive?), and for certain purposes specified herein, only, vTv Therapeutics Inc., a Delaware corporation (?vTv?). WHEREAS, the Company desires to continue to employ the Executive, and |
|
| December 9, 2020 |
5,331,306 Shares of Class A Common Stock 424B3 1 vtvt-424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-250934 PROSPECTUS 5,331,306 Shares of Class A Common Stock This prospectus relates to the resale or other disposition from time to time of up to 5,331,306 shares of our Class A common stock by Lincoln Park Capital Fund, LLC (the “selling stockholder” or “Lincoln Park”). The shares of our Class A common stock that ma |
|
| December 4, 2020 |
CORRESP 1 filename1.htm vTv Therapeutics Inc. 3980 Premier Drive, Suite 310 High Point, NC 27265 December 4, 2020 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Deanna Virginio vTv Therapeutics Inc. Registration Statement on Form S‑1 (File No. 333-250934) Dear Ms. Virginio: Pursuant to Rule 461 of the Securities Act |
|
| November 24, 2020 |
EX-99.1 4 vtvt-ex9916.htm EX-99.1 Exhibit 99.1 vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital HIGH POINT, N.C.-(GLOBE NEWSWIRE)— November 24, 2020 - vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“L |
|
| November 24, 2020 |
VTVT / vTv Therapeutics Inc / MacAndrews & Forbes Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 39)* vTv Therapeutics Inc. (Name of Issuer) Class A common stock, par value $0.01 per share (Title of Class of Securities) 918385 105 (CUSIP Number) Frances Townsend Vice Chairman, General Counsel and Chief Administrative Officer MacAndrews & Forbes Incorp |
|
| November 24, 2020 |
As filed with the Securities and Exchange Commission on November 24, 2020 Registration No. |
|
| November 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 24, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| November 24, 2020 |
EX-10.2 3 vtvt-ex10229.htm EX-10.2 Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 24, 2020, by and between VTV THERAPEUTICS INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized te |
|
| November 24, 2020 |
EX-10.1 2 vtvt-ex10130.htm EX-10.1 Exhibit 10.1 Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of November 24, 2020, by and between VTV THERAPEUTICS INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreemen |
|
| November 17, 2020 |
8-K 1 vtvt-8k20201116.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 16, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 00 |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv T |
|
| November 5, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 5, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| November 5, 2020 |
vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update EX-99.1 2 vtvt-ex9916.htm EX-99.1 Exhibit 99.1 vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update HIGH POINT, N.C. – (GLOBE NEWSWIRE) – November 5, 2020 – vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the progress of its clinical programs. “Following our decision to conclude enr |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): October 26, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 4 |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): September 30, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) |
|
| September 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 31, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47 |
|
| August 3, 2020 |
Exhibit 3.5 FIRST AMENDMENT TO VTV THERAPEUTICS INC. 2015 OMNIBUS EQUITY INCENTIVE PLAN This Amendment (this “Amendment”) to the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (the “Plan”) is effective as of August 3, 2020. WHEREAS, vTv Therapeutics Inc. (the “Company”) has adopted the Plan; WHEREAS, the Board may amend the Plan pursuant to Section 14(a) of the Plan, provided that stockh |
|
| August 3, 2020 |
EX-10.1 2 vtvt-ex101220.htm EX-10.1 Exhibit 10.1 THIRD amendment of VENTURE LOAN AND SECURITY AGREEMENT This THIRD AMENDMENT OF VENTURE LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of July 29, 2020, is entered into by and among vTv THERAPEUTICS INC. (“VTV INC”), vTv THERAPEUTICS LLC (“VTV LLC” and collectively with VTV INC, “Co-Borrowers”), HORIZON FUNDING TRUST 2019-1 (“Horizon Trust” |
|
| August 3, 2020 |
vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update Exhibit 99.1 vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update HIGH POINT, N.C. – (BUSINESS WIRE) – August 3, 2020 – vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020, and provided an update on the progress of its clinical programs. “Building on the successful phase 2 study completed earlier this year with TTP3 |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 vTv Therap |
|
| August 3, 2020 |
As filed with the Securities and Exchange Commission on August 3, 2020 Registration No. |
|
| August 3, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 3, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47- |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 23, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-3 |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 11, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-3 |
|
| May 22, 2020 |
DEFA14A 1 vtvt-defa14a20200522.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use |
|
| May 12, 2020 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 12, 2020 vTv Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37524 (Commission File No.) 47-39 |
